Kalshi to allow bets on clinical trials, FDA decisions

Kalshi is set to expand its platform by allowing users to place bets on the outcomes of clinical trials and FDA decisions. This move introduces new opportunities for speculation on pharmaceutical developments. However, the expansion of these betting options has raised concerns regarding the potential for increased market manipulation within the landscape of drug trials and regulatory approvals, as the platform integrates these specific medical and governmental milestones into its trading offerings.